Publication | Closed Access
Colistin(Coly-Mycin) in Resistant Bacterial Infections
50
Citations
2
References
1961
Year
Antimicrobial ChemotherapyAntibiotic ResistanceDrug ResistanceColistin SulfateInfection ControlAntibacterial MechanismsAlkaline SaltsAntimicrobial ResistanceResistant Bacterial InfectionsHealth SciencesMicrobial ToxinAntimicrobial PharmacokineticsAntimicrobial CompoundPharmacologyBacterial ResistanceClinical MicrobiologyAntimicrobial SusceptibilityAntibioticsMicrobiologyAntimicrobial PharmacodynamicsMedicineBacillus Colistinus
Among the new antibiotics investigated clinically in Houston during the past two years, colistin (Coly-Mycin) has been one of the most promising. This antibiotic was isolated in Japan by Yosuo Koyama in 1950 from culture filtrates of Bacillus colistinus, a bacterium closely related to Bacillus polymyxa, the source of the polymyxins. Its pharmacology has been studied in Japan, Italy, France, and, more recently, this country. A summary of the findings of these studies indicates that the chemical, pharmacological, and antimicrobial activity of colistin is closely related to the polymyxins, Clinically, however, colistin causes fewer undesirable side-effects. Colistin is a complex polypeptide, with an empirical formula of C<sub>45</sub>H<sub>85</sub>O<sub>10</sub>N<sub>13</sub>and a molecular weight of 969. Its acid salts are stable in solution even for very long periods; alkaline salts are less stable. It is available as colistin sulfate for oral and ophthalmic use, and as
| Year | Citations | |
|---|---|---|
Page 1
Page 1